antibodi
respons
neutral
human
immunodefici
mediat
direct
bind
viral
spike
trimer
compos
glycoprotein
pincu
et
al
pincu
et
al
blair
et
al
morri
et
al
micoli
et
al
pegu
et
al
hayn
mascola
liao
et
al
brodin
et
al
ward
wilson
debnath
et
al
moor
et
al
attach
viru
particl
target
cell
engag
viruscel
fusion
durham
chen
desai
et
al
dale
et
al
bieniasz
et
al
rausch
et
al
success
invitro
recombin
fail
gener
cross
neutral
antibodi
vivo
possibl
due
natur
conform
prevost
wang
et
al
door
et
al
door
et
al
zhou
et
al
wu
et
al
watkin
et
al
robertguroff
et
al
monoclon
antibodi
first
gener
mice
use
hybridoma
techniqu
patk
et
al
holzlohn
hanack
bhatia
et
al
pogson
et
al
abusneina
gauthier
milstein
subsequ
accept
global
manufactur
well
understood
rodent
murin
deriv
antibodi
immunogen
human
bind
antigen
within
human
bodi
complex
recogn
immunogen
agent
solv
problem
human
equival
form
gener
rodent
murin
antibodi
known
human
antibodi
pardi
et
al
wieh
et
al
rothenberg
bhowmick
et
al
hamanou
et
al
recent
year
new
techniqu
evolv
isol
human
monoclon
antibodi
directli
offer
advantag
reduc
immunogen
panel
specif
potent
broadli
neutral
antibodi
isol
recent
decad
first
gener
antibodi
use
combin
passiv
immun
morri
et
al
mehandru
et
al
armbrust
et
al
second
gener
antibodi
igg
observ
neutral
numer
viru
isol
nm
level
nm
equal
first
time
li
et
al
bunnik
et
al
ashish
et
al
zwick
et
al
sun
et
al
new
gener
potent
broadli
neutral
antibodi
includ
antibodi
ioma
neutral
viru
isol
rang
less
neutral
viru
isol
less
moral
et
al
huang
et
al
braibant
et
al
thenin
et
al
ring
et
al
euler
et
al
davenport
et
al
pancera
et
al
wu
et
al
scheid
scheid
et
al
worth
note
broadli
neutral
antibodi
neutral
test
virus
geometr
mean
bind
cellsurfac
envelop
oppos
phospholipid
bind
mper
reveal
highli
conserv
residu
critic
arginin
lysin
transmembran
region
breadth
potenc
demonstr
conserv
site
hiv
neutral
potenti
target
hiv
vaccin
design
huang
et
al
highli
potent
broadli
neutral
antibodi
bnab
individu
neutral
isol
antibodi
consid
sub
group
bnab
alreadi
isol
sever
infect
patient
neutral
differ
viru
isol
interact
hiv
bind
site
bnab
deriv
human
gene
famili
occupi
human
antibodi
repertoir
structur
studi
reveal
ab
interact
bind
site
mimick
molecul
specif
secondari
structur
form
heavi
chain
structur
light
chain
addit
import
delet
present
mani
ab
facilit
interact
bind
site
avoid
conflict
glycan
asn
loop
zhou
et
al
georgiev
et
al
wu
et
al
zhou
et
al
nextgener
sequenc
ng
deriv
sequenc
reveal
lineag
compris
least
six
distinct
heavi
chain
clade
five
light
chain
clade
observ
suggest
extraordinari
variat
antibodi
immun
may
occur
within
antibodi
lineag
even
singl
lineag
wu
et
al
gener
unmut
common
ancestor
antibodi
could
potenti
mechan
oppos
stimul
viru
coevolut
viru
unmut
common
ancestor
abil
matur
bnab
human
antibodi
elicit
b
cell
elimin
foreign
immunogen
directli
indirectli
antibodi
produc
neutral
foreign
antigen
variou
mechan
nonneutr
antibodi
perform
effector
function
mediat
nk
cell
via
antibodydepend
cellular
cytotox
adcc
liao
et
al
lin
et
al
thomann
et
al
ito
et
al
mandi
et
al
serum
immunoglobulin
produc
natur
human
immun
appli
passiv
immunotherapi
mani
infecti
diseas
sinc
approach
suffer
number
problem
polyclon
immunoglobulin
display
mix
efficaci
also
pose
potenti
threat
bloodborn
pathogen
transmiss
addit
resourc
serum
limit
expens
disadvantag
limit
applic
polyclon
immunotherapi
berri
steven
et
al
wang
et
al
sili
et
al
lang
et
al
recent
technolog
develop
made
possibl
isol
human
antibodi
vivo
vitro
sourc
improv
techniqu
includ
display
method
epsteinbarr
viru
ebv
immort
classic
hybridoma
procedur
singlecel
sort
follow
molecular
clone
techniqu
make
human
monoclon
antibodi
hybridoma
technolog
invent
product
mous
monoclon
antibodi
defin
antigen
specif
neutral
activ
applic
clinic
therapi
kelso
et
al
hugwil
tomita
tsumoto
martinlopez
et
al
hencsey
et
al
honda
et
al
milstein
hybridoma
gener
effect
fusion
b
cell
partner
cell
follow
screen
individu
antibodi
produc
cell
product
monoclon
antibodi
individu
hybridoma
cell
easili
quantifi
surfac
plasmon
reson
imag
stojanov
et
al
b
cell
hybridoma
import
sourc
screen
monoclon
antibodi
highthroughput
screen
use
character
mous
igg
antibodi
includ
subisotyp
bind
activ
neutral
activ
liu
et
al
szafran
et
al
fluoresc
antigen
use
sort
antigen
bind
hybridoma
cell
mixtur
oppos
tradit
way
screen
use
multimicro
well
plate
screen
limit
dilut
extens
technolog
cell
hybridoma
also
gener
krishnan
et
al
howev
mous
monoclon
antibodi
shown
problemat
human
due
immunogen
properti
low
effector
function
high
immunogen
prevent
applic
human
prolong
dose
requir
differ
sequenc
glycosyl
pattern
fc
region
make
rodent
mab
poorli
effect
mediat
effector
function
human
li
et
al
human
b
cell
prove
difficult
immort
use
hybridoma
techniqu
li
et
al
cafri
et
al
park
et
al
primari
issu
mab
produc
human
b
cell
hybridoma
cell
could
react
selfantigen
addit
lack
suffici
matur
outsid
germin
center
low
bind
affin
mab
deriv
hybridoma
meant
screen
clone
typic
react
target
antigen
due
problem
antibodi
human
develop
altern
gener
human
format
antibodi
rodent
deriv
antibodi
martin
ree
choi
et
al
olimpieri
et
al
safdari
et
al
tsurushita
et
al
ohtomo
et
al
human
antibodi
produc
method
genet
engin
potenti
reduc
immun
respons
nonhuman
deriv
antibodi
done
combin
variabl
v
region
bind
domain
rodent
antibodi
human
antibodi
constant
c
region
kind
chimer
antibodi
retain
bind
specif
less
immunogen
human
case
chimer
antibodi
retain
effect
mediat
human
complementdepend
cytotox
cdc
adcc
also
possibl
produc
human
antibodi
without
creat
chimer
intermedi
first
precis
sequenc
desir
cdr
known
dna
sequenc
directli
clone
antibodi
express
vector
human
antibodi
scaffold
wide
varieti
human
antibodi
express
vector
develop
use
method
exampl
vector
human
antibodi
express
vector
origin
use
express
human
potent
neutral
antibodi
igg
antibodi
clone
differ
clone
vector
describ
previous
tiller
et
al
tiller
et
al
anoth
method
immort
human
memori
b
cell
epsteinbarr
viru
ebv
mediat
transform
lee
et
al
klein
straub
zubler
ohashi
et
al
mclaughlin
et
al
traggiai
et
al
ebvbind
receptor
posit
b
cell
immort
gener
antibodi
isol
use
singl
cell
sort
cultur
feeder
cell
screen
clone
optim
methodolog
activ
b
cell
use
tolllik
receptor
agonist
cpg
dna
ebv
infect
use
isol
human
monoclon
antibodi
variou
pathogen
virus
katsumura
et
al
bass
dark
sun
et
al
also
report
human
b
cell
immort
transform
retroviru
encod
antiapoptot
factor
b
cell
lymphoma
bclxl
presenc
interleukin
ligand
schrader
et
al
rydstrom
et
al
kusam
et
al
process
trigger
memori
b
cell
differenti
antibodi
secret
cell
immort
human
b
cell
provid
substanti
resourc
human
b
cell
subsequ
screen
cultur
week
antibodi
collect
isol
supernat
perform
neutral
differ
virus
immort
b
cell
also
sort
antigen
use
flowbas
technolog
heavi
light
chain
gene
antibodi
secret
immort
b
cell
clone
famou
antibodi
gener
method
buchach
et
al
howev
due
low
effici
ebvinduc
b
cell
transform
method
limit
applic
though
optim
method
studi
base
ebvinduc
b
cell
transform
effici
still
need
dramat
improv
sun
et
al
lu
et
al
kwakkenbo
et
al
report
show
memori
b
cell
cultur
shortterm
supernat
use
directli
screen
neutral
activ
high
throughput
neutral
assay
microneutr
number
famou
neutral
antibodi
isol
base
method
includ
huang
et
al
ring
et
al
walker
et
al
walker
et
al
falkowska
et
al
potent
neutral
antibodi
classic
antibodi
isol
microneutr
origin
isol
activ
memori
b
cell
one
clade
infect
donor
screen
approxim
character
hiv
infect
donor
memori
b
cell
cultur
clonal
densiti
purpos
clone
antibodi
heavi
light
chain
pair
cultur
well
neutral
viral
isol
neutral
virus
median
potenc
less
antibodi
isol
memori
b
cell
sort
cultur
express
feeder
cell
neutral
test
pseudovirus
test
virus
valu
ugml
b
cell
cultur
microneutr
isol
potent
broadli
neutral
antibodi
howev
larg
scale
screen
b
cell
make
method
labor
intens
costli
addit
low
yield
typic
ten
antigenspecif
clone
isol
ten
thousand
b
cell
fig
b
current
report
ebv
transform
optim
effici
enabl
gener
immort
b
cell
librari
howev
effici
still
need
improv
enabl
greater
b
cell
surviv
sun
et
al
phage
display
librari
method
permit
screen
antibodi
larg
recombin
librari
falkowska
et
al
boot
et
al
chan
et
al
aghebatimaleki
et
al
rahbarnia
et
al
finlay
et
al
antibodi
display
form
either
singl
chain
variabl
fragment
scfv
antigenbind
fragment
fab
recent
report
show
singl
domain
antibodi
also
display
phage
display
system
duart
et
al
kazemilomedasht
et
al
li
et
al
rotman
et
al
tang
et
al
mani
antibodi
differ
virus
includ
rabi
viru
sever
acut
respiratori
syndrom
sar
viru
ebola
viru
yellow
fever
viru
hepat
c
viru
dengu
viru
hepat
viru
influenza
viru
hiv
success
isol
use
technolog
principl
phage
display
techniqu
isol
antibodi
construct
phage
display
recombin
antibodi
librari
first
recombin
antibodi
librari
increas
divers
antibodi
b
cell
repertoir
promot
screen
antibodi
novel
properti
grau
et
al
antibodi
librari
gener
construct
randomli
assembl
antibodi
heavi
light
chain
variabl
region
gene
shuffl
heavi
light
chain
increas
divers
summari
phage
display
creat
greater
divers
antibodi
provid
rapid
high
throughput
way
screen
crossreact
human
monoclon
antibodi
isol
recombin
phage
display
librari
competit
antigen
pan
zhang
et
al
zhang
et
al
zhang
et
al
zhang
et
al
zhang
et
al
specif
crossreact
antibodi
recogn
anoth
potent
neutral
antibodi
isol
phage
display
recombin
antibodi
librari
consid
one
potent
neutral
antibodi
isol
phage
display
neutral
known
isol
li
et
al
manti
et
al
haussner
et
al
wu
et
al
consid
standard
antibodi
isol
phage
display
howev
potenc
much
lower
antibodi
isol
micro
neutral
andor
phage
display
select
antibodi
vitro
antibodi
express
phage
system
may
necessarili
repres
mammalian
cell
due
differ
protein
fold
post
transcript
modif
difficult
draw
direct
conclus
gain
understand
natur
occurr
antibodi
heavi
light
chain
select
base
phage
display
alon
zhang
et
al
avoid
limit
display
method
develop
display
antibodi
surfac
yeast
mammalian
cell
sort
flow
cytometri
accord
antigen
specif
known
yeast
surfac
display
becom
power
engin
tool
display
recombin
protein
surfac
saccharomyc
cerevisia
via
genet
fusion
traxlmayr
shusta
mei
et
al
andreu
del
olmo
sheehan
marasco
gera
et
al
boder
et
al
yeast
surfac
display
eukaryot
express
system
capabl
induc
post
translat
modif
recombin
antibodi
yeast
cell
express
fusion
recombin
protein
allow
applic
cell
sort
specif
antigen
yeast
display
system
report
use
isol
antibodi
also
report
use
display
antigen
recombin
protein
srivastava
et
al
guo
et
al
panel
yeast
display
antigen
librari
construct
includ
yeast
display
antigen
epitop
librari
yeast
display
siv
antigen
epitop
librari
epitop
map
specif
antibodi
isol
display
techniqu
less
potent
isol
micro
neutral
singl
b
cell
sort
clone
howev
recent
studi
phageyeast
display
show
great
potenti
isol
singl
domain
antibodi
recombin
librari
singledomain
antibodi
consid
separ
class
antibodi
compos
antibodi
fragment
consist
singl
monomer
antibodi
domain
singledomain
antibodi
allow
broad
rang
applic
due
small
molecular
mass
size
effici
product
high
affin
singl
domain
antibodi
label
use
fluoresc
molecul
diagnost
purpos
biotechnolog
usag
conjunct
drug
toxin
singl
domain
antibodi
also
use
therapeut
applic
wellstudi
singl
domain
antibodi
antibodi
heavychain
variabl
domain
dna
sequenc
optim
order
improv
stabil
addit
heavychain
variabl
domain
type
singl
domain
antibodi
studi
includ
antibodi
lightchain
variabl
domain
antibodi
form
nanobodi
duart
et
al
li
et
al
gong
et
al
loui
et
al
lulf
et
al
bouchet
et
al
bouchet
et
al
boudet
et
al
mammalian
cell
display
power
method
isol
antibodi
scfv
format
full
length
igg
high
affin
shown
singl
chain
antibodi
display
surfac
human
cell
use
affin
matur
soga
et
al
tomimatsu
et
al
beerli
et
al
mammalian
cell
express
system
ensur
cellular
compon
involv
process
antibodi
synthesi
isol
human
antibodi
mammalian
cell
display
benefit
advantag
mammalian
cell
express
systemmammalian
cell
display
reli
transfect
antibodi
express
vector
comparison
yeast
display
system
mammalian
cell
express
system
allow
multipl
recombin
proteinantibodi
deliv
vector
one
cell
thu
modif
enrich
singl
clone
isol
need
pan
purpos
fig
import
advanc
antibodi
screen
clone
technolog
develop
singl
cell
sort
singl
cell
revers
transcript
pcr
ouiss
et
al
evan
et
al
batty
et
al
human
singl
b
cell
differ
antigen
specif
sort
flow
cytomet
directli
origin
vh
vl
pair
antibodi
singl
human
b
cell
amplifi
high
effici
way
requir
rel
cell
number
methodolog
quit
effici
obtain
antibodi
heavi
light
chain
extrem
rare
highli
discret
b
cell
subpopul
fig
memori
b
cell
plasma
cell
ideal
cell
type
purpos
monoclon
antibodi
clone
due
specif
cell
type
method
alway
combin
singl
cell
clone
flow
cytometri
base
singl
cell
sort
sort
antigen
specif
b
cell
thu
accur
probe
design
sort
essenti
protein
ideal
probe
reactiv
mani
antibodi
includ
nonneutr
strong
bind
antibodi
wu
et
al
wu
et
al
zhou
et
al
one
success
exampl
probe
design
fish
potent
broadli
neutral
monoclon
antibodi
agent
pair
computerassist
design
sort
individu
b
cell
express
antibodi
resurfac
stabil
core
function
structur
core
bind
site
loop
delet
preserv
antigen
structur
bind
site
elimin
antigen
region
substitut
simian
immunodefici
viru
siv
residu
contain
one
amino
acid
delet
posit
singl
amino
acid
mutat
knock
function
bind
site
bind
site
antibodi
like
bind
effici
fail
bind
potent
broadli
neutral
antibodi
isol
singl
b
cell
posit
sort
neg
sort
neutral
test
pseudovirus
test
virus
valu
ugml
wu
et
al
wu
et
al
mccoy
burton
ioma
anoth
two
success
bnmab
isol
reason
probe
design
singl
cell
sortingclon
gristick
et
al
freund
et
al
nglycan
trimer
envelop
glycoprotein
env
accommod
broadli
neutral
antibodi
engin
crystal
structur
env
trimer
expos
nativ
glycan
shield
highmannos
complextyp
n
z
sun
et
al
viru
research
glycan
use
fish
bnmab
ioma
new
site
antibodi
thu
defin
heavi
chain
ioma
deriv
consid
germlin
gene
bnab
light
chain
lack
short
defin
bnab
three
bnab
isol
singl
igg
b
cell
sort
use
four
differ
fish
agent
four
separ
sort
core
mixtur
clade
clade
c
sok
et
al
dey
et
al
yang
et
al
sander
et
al
kovac
et
al
antibodi
target
portion
envelop
neutral
virus
panel
test
geometr
mean
mgml
antibodi
show
geometr
mean
mgml
respect
bind
quaternari
trimer
epitop
core
overlap
bind
region
antigen
bait
fish
proven
quit
success
isol
hivspecif
human
monoclon
igg
express
b
cell
igm
express
b
cell
infect
donor
use
cleverli
engin
antigen
probe
flow
cytometri
base
singl
cell
sort
clone
also
appli
understand
natur
select
antibodi
clone
antibodi
b
cell
differ
infect
stage
one
donor
b
cell
stage
differ
donor
deep
sequenc
allow
studi
matur
specif
antibodi
popul
correspond
b
cell
subpopul
stimul
viru
isol
progressingstag
infect
morri
et
al
banerje
et
al
carter
et
al
karlsson
hedestam
et
al
soto
et
al
stramer
et
al
zhu
et
al
zhu
et
al
difficulti
elicit
bnab
immun
anim
conclud
walker
et
al
sander
et
al
sok
et
al
enorm
antigen
divers
envelop
glycoprotein
nlink
glycan
shield
consid
two
major
point
recent
studi
show
success
rapid
elicit
broadli
neutral
antibodi
immun
cow
jrfl
sosip
immun
cow
strong
immun
respons
observ
broadli
neutral
antibodi
isol
peripher
blood
mononuclear
cell
pbmc
sort
biotinyl
sosip
broadli
neutral
antibodi
display
neutral
breadth
potent
median
ml
panel
testedthi
studi
give
light
investig
gener
antibodi
pathogen
evolv
avoid
human
antibodi
respons
anim
recent
decad
technolog
advanc
allow
specif
human
antibodi
isol
directli
human
b
cell
recombin
librari
isol
human
monoclon
antibodi
use
therapi
safeti
effici
specif
toler
human
thu
power
tool
fight
pathogen
among
develop
antibodi
isol
method
last
decad
difficult
highlight
one
sole
prefer
method
differ
methodolog
differ
advantag
display
techniqu
base
recombin
librari
use
isol
singl
domain
antibodi
enlarg
librari
size
techniqu
provid
us
inform
origin
pair
heavi
chain
light
chain
specif
antibodi
singl
b
cell
sort
cultur
facilit
rapid
clone
potent
neutral
antibodi
requir
larg
labor
cost
reason
design
probe
develop
nativelik
stabil
trimer
greatli
improv
effici
screen
function
envelopebind
b
cell
thu
hard
conclud
best
way
gener
novel
bnab
combin
method
use
screen
isol
potent
neutral
antibodi
order
maxim
advantag
differ
method
meanwhil
develop
novel
methodolog
broadli
neutral
antibodi
isol
screen
encourag
broaden
knowledg
enlarg
recours
antibodi
class
purpos
method
base
singl
cell
sort
viral
neutral
instead
fish
agent
provid
direct
effici
way
minimum
workload
addit
passiv
treatment
present
anoth
import
purpos
isol
character
potent
broadli
neutral
antibodi
function
studi
neutral
epitop
provid
key
knowledg
effici
vaccin
design
human
broadli
neutral
antibodi
serv
potenti
sourc
discov
neutral
epitop
target
fight
mani
infecti
diseas
thu
facilit
design
vaccin
antibodi
structur
studi
provid
new
insight
mechan
recognit
immun
evas
epitop
atom
level
antibodi
matur
captur
viru
mutant
moral
et
al
wibmer
et
al
ruja
et
al
howev
recent
report
immunogen
candid
report
elicit
potent
broadli
neutral
antibodi
sever
immun
studi
nativelik
envelop
trimer
report
induc
neutral
antibodi
viru
rabbit
even
though
potenc
much
weaker
comparison
broadli
neutral
antibodi
isol
human
long
term
nonprogressor
sander
et
al
bradley
et
al
prestimul
b
cell
heterogen
epitop
antigen
show
improv
stimul
b
cell
gener
potent
neutral
antibodi
yang
et
al
also
report
germlinetarget
stabil
trimer
immunogen
prime
respons
inferredgermlin
knock
mice
highlight
hypothesi
primeboost
sequenti
immun
strategi
steichen
et
al
observ
highlight
neutral
antibodi
role
prevent
altogeth
understand
antibodi
gener
function
mechan
help
guid
effici
vaccin
design
produc
effect
therapi
applic
applic
applic
applic
author
claim
interest
